{"id":"placebo-a-after-cp","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this agent contains no active pharmaceutical ingredient and produces no direct molecular or biological effect. It is used as a control comparator in clinical trials to assess the efficacy of active treatments by isolating the true drug effect from placebo response and natural disease progression.","oneSentence":"Placebo A is an inert control substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:25.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT07329387","phase":"NA","title":"Effectiveness of NMES in Swallowing Rehabilitation in Children With CP","status":"COMPLETED","sponsor":"Necmettin Erbakan University","startDate":"2018-05-01","conditions":"Cerebral Palsy (CP)","enrollment":26},{"nctId":"NCT06964815","phase":"NA","title":"Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients","status":"RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2025-11-12","conditions":"Glioblastoma, IDH Wild-type and STAT3-positive Glioblastoma","enrollment":110},{"nctId":"NCT04612738","phase":"NA","title":"Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-03-19","conditions":"Advance Care Planning, Advance Directives, Terminal Illness","enrollment":1500},{"nctId":"NCT03519971","phase":"PHASE3","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-29","conditions":"Non-Small Cell Lung Cancer","enrollment":328},{"nctId":"NCT06159114","phase":"PHASE4","title":"Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS","status":"COMPLETED","sponsor":"Xintian Pharmaceutical","startDate":"2023-12-19","conditions":"Chronic Prostatitis","enrollment":246},{"nctId":"NCT06860841","phase":"PHASE4","title":"Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Campus Bio-Medico University","startDate":"2025-01-10","conditions":"Type 2 Diabetes, Overweight and Obese Adults","enrollment":16},{"nctId":"NCT04877756","phase":"PHASE2","title":"Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery","status":"COMPLETED","sponsor":"Olix Pharmaceuticals, Inc.","startDate":"2021-08-19","conditions":"Hypertrophic Scar","enrollment":22},{"nctId":"NCT03748134","phase":"PHASE3","title":"Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-12-24","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":746},{"nctId":"NCT01493843","phase":"PHASE2","title":"Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-01-20","conditions":"Non-Small Cell Lung Cancer","enrollment":501},{"nctId":"NCT02329561","phase":"PHASE1","title":"PK PD of the Enantiomers of Tramadol and O-desmethyltramadol in Elderly and Young Subjects","status":"COMPLETED","sponsor":"Université de Montréal","startDate":"2007-01","conditions":"Aging, Pain","enrollment":35},{"nctId":"NCT00723528","phase":"PHASE3","title":"An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-03","conditions":"Psoriasis","enrollment":158},{"nctId":"NCT00747344","phase":"PHASE3","title":"A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-12","conditions":"Psoriasis","enrollment":121},{"nctId":"NCT01491191","phase":"NA","title":"Palmitoylethanolamide for Post-operative Pain Prevention","status":"UNKNOWN","sponsor":"University of Modena and Reggio Emilia","startDate":"2012-01","conditions":"Chronic Post-operative Pain","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":337,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo A (After CP)","genericName":"Placebo A (After CP)","companyName":"Janssen Pharmaceutical K.K.","companyId":"janssen-pharmaceutical-k-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}